The Syntheses of Triazole,Sulfur-Containing Diazole and n-Phenylthiatriazole Biphenyltetrazoles as Potential Angiotensin II Receptor Antagonists

The syntheses of triazole, sulfur-containing diazole and N-phenylthiatriazole analogs of imidazole angiotensin II antagonist, DuP 753, are reported. 5-Butyl-3-[(2-trifluoromethyl)phenyl]-2,1,3,4-lH-thiatriazole-2-one biphenyltetrazole ( 63 ) is found to have good in vitro activity.     

Structural characterization of two oxadiazolic systems used as spacers for potential angiotensin II receptor antagonists

The structures of two oxadiazole derivatives, methyl 2-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]benzoate (1) and methyl 2-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]benzoate2, used as spacers in the synthesis of new potential non-peptide angiotensin receptor antagonists have been determined by X-ray crystallography. In both compounds π-π interactions were observed between the oxadiazole rings and the phenyl rings of neighboring molecules. In the crystal packing of the oxadiazole 2 two C-H?O interactions are present.     

Studies on 1, 2, 4-Benzothiadiazine 1, 1-Dioxide IX.1 Synthesis and Pharmacological Evaluation of 1, 2, 4-Benzothiadiazine 1, 1-Dioxide Biphenyl Tetrazoles as Angiotensin II Antagonists

In the course of our investigations on the development of cardiovascular agents, 3-butyl-2-[2′-(2H-tetrazol-5-yl)bipheny]-4-yl]methyl-2H-1, 2, 4-benzothiadiazine 1, 1-dioxide ( 2 ) was considered as a potential angiotensin II antagonist on the basis of bioisosteric replacement of the quinazoline ring of compound 1 with a 1, 2, 4-benzothiadiazine 1, 1-dioxide ring system. Alkylation of 6 with 4 afforded 7 and 8 in 24% and 28% yields, respectively. An attempt to remove the trityl group of compounds 7 and 8 under acidic condition gave the ring opened products 9 and 11 in 28% and 36% yields, respectively. However, compounds 2 and 10 were obtained in 46% and 85% yields when compounds 7 and 8 were refluxed in methanol. Preliminary assays of compounds 9 and 11 against angiotensin II receptors revealed weak activity with IC₅₀ values of 3.6 μM and 5.4 μM, respectively. Compound 10 (IC₅₀ = 87 nM) exhibited stronger binding affinity than compound 2 (IC₅₀ = 750 nM).     

Synthesis and in Vitro Evaluation of N-[[4-[2-(Carboxyl)-1-Cycloalken-1-yl]Phenyl]Methyl]Imidazoles as Nonpeptide Angiotensin II Receptor Antagonists

A series of nonpeptide angiotensin II receptor antagonists was synthesized via palladium-assisted cross coupling of aryl stannane and cycloalkenyl triflates and subsequent alkylation of silyl-protected imidazole. Our compounds, which have a terminal five- to seven-membered cycloalkenyl ring, are compared to DuPont EXP7711, an N-[(2′-carboxybiphenylyl)methyl]imidazole, which has a terminal phenyl moiety. Physicochemical properties of the compounds, such as lipophilicity, steric bulk, conformation, and the relative spatial proximity of the 2-carboxyl and the middle phenyl, are quantitated by computational chemistry. Potency in terms of binding affinity to AT₁ receptors in rat adrenal glomerulosa and rabbit aorta is maximized when the terminal ring is aromatic.     

QSAR study of angiotensin II antagonists using robust boosting partial least squares regression

In the current study, robust boosting partial least squares (RBPLS) regression has been proposed to model the activities of a series of 4H-1,2,4-triazoles as angiotensin II antagonists. RBPLS works by sequentially employing PLS method to the robustly reweighted versions of the training compounds, and then combing these resulting predictors through weighted median. In PLS modeling, an F-statistic has been introduced to automatically determine the number of PLS components. The results obtained by RBPLS have been compared to those by boosting partial least squares (BPLS) repression and partial least squares (PLS) regression, showing the good performance of RBPLS in improving the QSAR modeling. In addition, the interaction of angiotensin II antagonists is a complex one, including topological, spatial, thermodynamic and electronic effects.     

Rational Design and Synthesis of AT1R Antagonists

Hypertension is one of the most common diseases nowadays and is still the major cause of premature death despite of the continuous discovery of novel therapeutics. The discovery of the Renin Angiotensin System (RAS) unveiled a path to develop efficient drugs to fruitfully combat hypertension. Several compounds that prevent the Angiotensin II hormone from binding and activating the AT1R, named sartans, have been developed. Herein, we report a comprehensive review of the synthetic paths followed for the development of different sartans since the discovery of the first sartan, Losartan.     

选择性M3受体拮抗剂的研究进展

M3受体是毒蕈碱型乙酰胆碱受体的亚型之一,在人体内分布广泛。选择性M3受体拮抗剂可以竞争性地与M3受体结合,主要用于膀胱过度活动症(OAB)、慢性阻塞性肺病(COPD)和肠道易激综合症(IBS)等疾病的治疗。与非选择性拮抗剂相比,选择性M3受体拮抗剂对中枢神经以及心脏的副作用大大降低。本文对已上市及处在不同研究阶段的选择性M3受体拮抗剂进行了综述。     

Novel Method for Synthesis of Diarylpyrazole Derivatives as Cannabinoid CB_1 Receptor Antagonists

A novel and efficient method was developed for the synthesis of diarylpyrazole derivatives as cannabinoid CB1 receptor antagonist via four step reactions. The key step was the synthesis of a diarylpyrazole skeleton, which involved initial condensation of the sodium salt of compound 12 with diazonium compounds, and further cyclization by heating at reflux in acetic acid. Eight diarylpyrazole derivatives and nine new synthesized compounds were characterized by 1H NMR, IR, MS, and elemental analysis. The react...     

Application of High-Performance Thin-Layer Chromatography for Screening and Simultaneous Determination of Some Angiotensin II Receptor Antagonists in Dosage Forms and Plasma

JPC – Journal of Planar Chromatography – Modern TLC - A high-performance thin-layer chromatographic (HPTLC) method was performed for simultaneous quantification of four angiotensin II...     

Magnetic solid‐phase extraction of angiotensin II receptor antagonists in human urine and plasma with a reversed‐phase/cation‐exchange mixed‐mode sorbent

Biocompatible magnetic nanoparticles that featured divinylbenzene and sulfonate functionalities were used for the magnetic solid‐phase extraction of five angiotensin II receptor antagonists from human urine and plasma samples based on a reversed‐phase and cation‐exchange mixed‐mode mechanism. Under the optimized extraction conditions, coupled to high‐performance liquid chromatography with fluorescence detection, this proposed method was found to be accurate and precise with relative standard deviations of less than 11.7%, and a good recovery of 80.1–119.5% for both samples. The linear ranges were 0.2–2000 and 0.2–2500 ng/mL along with correlation coefficients above 0.9923 and 0.9928 for urine and plasma samples, respectively. Limits of detection were 0.01–5.74 and 0.01–1.31 ng/mL, respectively. The proposed magnetic solid‐phase extraction based on the magnetic nanoparticles functionalized with divinylbenzene and sulfonate was a reliable and convenient sample pretreatment method and had the potential for isolating and enriching the angiotensin II receptor antagonists in biological samples.     

Actions of Novel Angiotensin Receptor Blocking Drugs,Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System

Angiotensin receptor blockers (ARBs) used in the treatment of hypertension and potentially in SARS-CoV-2 infection exhibit inverse agonist effects at angiotensin AR1 receptors, suggesting the receptor may have evolved to accommodate naturally occurring angiotensin ‘antipeptides’. Screening of the human genome has identified a peptide (EGVYVHPV) encoded by mRNA, complementary to that encoding ANG II itself, which is an inverse agonist. Thus, opposite strands of DNA encode peptides with opposite effects at AR1 receptors. Agonism and inverse agonism at AR1 receptors can be explained by a receptor ‘switching’ between an activated state invoking receptor dimerization/G protein coupling and an inverse agonist state mediated by an alternative/second messenger that is slow to reverse. Both receptor states appear to be driven by the formation of the ANG II charge-relay system involving TyrOH-His/imidazole-Carboxylate (analogous to serine proteases). In this system, tyrosinate species formed are essential for activating AT1 and AT2 receptors. ANGII is also known to bind to the zinc-coordinated metalloprotease angiotensin converting enzyme 2 (ACE2) used by the COVID-19 virus to enter cells. Here we report in silico results demonstrating the binding of a new class of anionic biphenyl-tetrazole sartans (‘Bisartans’) to the active site zinc atom of the endopeptidase Neprilysin (NEP) involved in regulating hypertension, by modulating humoral levels of beneficial vasoactive peptides in the RAS such as vasodilator angiotensin (1–7). In vivo and modeling evidence further suggest Bisartans can inhibit ANG II-induced pulmonary edema and may be useful in combatting SARS-CoV-2 infection by inhibiting ACE2-mediated viral entry to cells.     

Determination of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a New Angiotensin Type 1 Receptor Antagonist in Rat Plasma by LC-ESI-MS: Application to Pharmacokinetic Studies

A simple and sensitive reversed-phase LC-ESI-MS method to identify and quantitate 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one (1b), a new Angiotensin II type 1 receptor antagonist in rat plasma has been developed and validated. Sample preparation used a simple liquid–liquid extraction with ethyl acetate. Separation was achieved by gradient elution on a C₁₈ column. The mobile phase consisted of acetonitrile and water (0.05% triethylamine and 0.05% acetic acid) at a flow rate of 0.2 mL min⁻¹. The detection utilized selected ion monitoring (SIM) in the negative mode at m/z 507.1 and m/z 407.2 for the deprotonated molecular ions of 1b and the internal standard irbesartan, respectively. The lower limit of quantification was reproducible at 5 ng mL⁻¹ with 100 μL of plasma and the good linear was observed in the 5–500 ng mL⁻¹ range. This concentration range corresponded well with the plasma concentrations of 1b in pharmacokinetic studies. Recoveries of 1b in rat plasma were 76.1, 74.6 and 79.0% at 5, 50 and 500 ng mL⁻¹. The RSD of intra-assay and inter-assay variations were all less than 5%. This validated LC-ESI-MS assay is an economic, quick, precise and reliable method for the analysis of 1b in pharmacokinetic studies.     

Identification of the Metabolites of Angiotensin II (1-8) in MES-13 Cells by a Simple NanoLC-MS-MS System: A Preliminary Platform

The renin-angiotensin system (RAS) participates in regulating the body fluid, such as angiotensin II (1-8), and plays an important role in blood pressure control. In RAS, angiotensin II (1-8) is the major effector but other angiotensins may also mediate the actions of the RAS. In this study, a simple method is proposed for analysis of the metabolites of angiotensin II (1-8). Experimental data was acquired by a nanoLC system connected with quadruple time-of-flight (Q-TOF) mass spectrometry. The flow rate of this method was at 400 nL/min, and this nanoliter level flow rate would lower the consumption of organic solvents.     

Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity

Hydroxymethylthiohydantoin, hydroxymethylthiohydantoin, and hydantoin, containing a pyridine group, were synthesized to study their androgen receptor antagonistic activities. Among them, compounds 6a/6c/7g/19a/19b exhibited excellent androgen receptor antagonistic activity, which was consistent with or even superior to enzalutamide. In addition, compounds 19a and 19b exhibited better antiproliferative activity than enzalutamide in prostate cancer cells. The results show that compound 19a has great potential as a new AR antagonist.     

人类腺苷受体A3亚型拮抗剂的构效关系分析

构建人类腺苷受体A3亚型药效团模型和三维蛋白结构模型用于作用模式研究.以18个来源于文献具有腺苷受体A3亚型拮抗活性的化合物作为训练集,使用HypoGen方法构建药效团模型.通过同源模建和分子动力学模拟构建了人类腺苷受体A3亚型的三维蛋白模型,并利用PROCHECK方法评估该模型的合理性,对所得的结构使用分子对接程序进行作用模式分析,药效团模型和同源模建结果相互匹配较好.使用新药效团模型对MDL药物数据库(MDDR)中包含的约120000个化合物进行虚拟筛选,得到了8个候选化合物,用于进一步的生物学评价和活性测定.本工作对于人类腺苷受体A3亚型拮抗剂的设计和抗哮喘药物的研发具有一定的理论指导和应用价值.